trial · primary record
SC-102
Advanced Solid Cancers
| Phase | Phase 1 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 120 |
| Primary completion | 2027-12-30 |
| Primary endpoint | Number of participants receiving SC-102 treatment with treatment-emergent adverse events (escalation study) |
| Registry ID | NCT06710158 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:41:49.653Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06710158
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.